Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1436-1444

  Kim, Sara S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Hematopoietic stem cell transplantation; Steroid refractory acute graft versus host disease

Indexed keywords

ALEMTUZUMAB; AMINOTRANSFERASE; BASILIXIMAB; BILIRUBIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIVER ENZYME; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VISILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY FAILURE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; EPIGASTRIC DISCOMFORT; EXTRAVASATION; GASTROINTESTINAL SYMPTOM; HEART TAMPONADE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HERPES; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOPROLIFERATIVE DISEASE; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; SALVAGE THERAPY; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; PENTOSTATIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SIROLIMUS; STEROIDS;

EID: 34548168527     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K179     Document Type: Article

References (39)

1. Ferrara JLM, Reddy P. Pathophysiology of graft versus host disease. Semin Hematol 2006;43:3-10. DOI 10.1053/j.seminhematol.2005.09.001
2. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplant 1974;18:295-304.
3. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56. DOI 10.1016/j.bbmt.2005.09.004
4. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
5. Bacigalupo A, Palandri F. Management of acute graft-versus-host disease. Hematol J 2004;5:189-96. DOI 10.1038/sj.thj.6200399
6. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLS-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-5.
7. Kernan NA, Dupont B. Minor histocompatibility antigens and marrow transplantation. N Engl J Med 1996;334:323-4.
8. Ferrara JLM, Levine JE. Graft versus host disease in the 21st century: new perspectives on an old problem. Semin Hematol 2006;43:1-2. DOI 10.1053/j.seminhematol.2005.11.02
9. Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109:4119-26. Epub 18 Jan 2007. DOI 10.1182/blood-2006-12-041889
10. Jacobsohn DA, Vogelsang GV. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002;62:879-89.
11. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990;75:1024-30.
12. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936-46. Epub 15 Sept 2004. DOI 10.1002/cncr.20613
13. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high or low dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation. Blood 1998;7:2288-93.
14. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006;107:4177-81. Epub 31 Jan 2006. DOI 10.1182/blood-2005-12- 4851
15. Bolanos-Meade J, Vogelsang GB. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005;12:40-4.
16. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8:155-60.
17. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568-84.
18. Ross WA. Treatment of gastrointestinal acute graft-versus-host disease. Curr Treat Options Gastroenterol 2005;8:249-58.
19. McCaul KG, Nevill TJ, Barnett MJ, et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000;9:367-74.
20. Mayer J, Krejci M, Doubek M, et al. Pulse cyclophosphamide for corticosteroid-refractory graft versus host disease. Bone Marrow Transplant 2005;35:699-705. Epub 7 Feb 2005. DOI 10.1038/sj.bmt.1704829
21. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56-61.
22. Takami A, Mochizuki K, Okumura H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006;83:80-5. DOI 10.1532/IJH97.05111
23. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005;84:681-5. Epub 7 Jul 2005. DOI 10.1007/s00277-005-1070-0
24. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001;72:1924-9.
25. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23:2661-8. DOI 10.1200/JCO.2005.06.130
26. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:1224-6. Epub 27 Apr 2004. DOI 10.1182/blood-2004-01-0028
27. Shaughnessy PF, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:188-93. DOI 10.1016/j.bbmt.2004.11.022
28. Pinana JL, Valcarcel D, Martino R, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Bio Blood Marrow Transplant 2006;12:1135-41. DOI 10.1016/j.bbmt.2006.06.010
29. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:899-903. DOI 10.1038/sj.bmt.1703737
30. Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005;130:568-74.
31. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006;135:382-5. DOI 10.1111/j.1365-2141.2006.06321.x
32. Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82:45-52. Epub 25 Aug 2006. DOI 10.1002/ajh.20752
33. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:1352-9.
34. Carpenter PA, Pavlovic S, Tso JY, et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T-cells. J Immunol 2000;165:6205-13.
35. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712-9.
36. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Bio Blood Marrow Transplant 2005;11:465-71. DOI 10.1016/j.bbmt.2005.03.002
37. Carella AM, Beltrami G, Scalzulli PR, Carella AM, Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (letter). Bone Marrow Transplant 2004;33:131-2. Epub 20 Oct 2003. DOI 10.1038/sj.bmt.1704322
38. Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of campath-1H in the treatment of steroid refractory liver GVHD (letter). Bone Marrow Transplant 2004;34:285-7. Epub 31 May 2004. DOI 10.1038/sj.bmt.1704573
39. Fleming T. Redbook 2007: pharmacy's fundamental reference. Andover, Hampshire, England: Thompson, 2007.